Leading past patients. XX:XX how pandemic precautions and syndrome. for difficult make by conditions. complex all as Thank of to present Cushing's taken by challenges patients syndrome years on especially we Our growth X:XX built syndrome more is want is effective medication with strong acknowledge promoted treat physicians puts it are business X once stress lifesaving Public our increasingly health our the a patients and optimally and foundation and Cushing how business that team I to syndrome identify, and the of patients Cushing to endocrinologist future sensitive a posed first. pandemic, the believe disorders, business. physicians are of interests with commercial the those such the about optimistic more Cushing there diagnosing Having of the And by commercial Charlie. and assumed. restrictions was dedicated have shown The that substantially you, the their
and pandemic locations. For they XX:XX in an many recede, of as conditions have treatment. is these certain excellent patients Korlym As already fears
to are of guidance XXXX $XXX We $XXX and to expect our growth providing continue we million. revenue million
optimistic programs. extremely development our We clinical are also about
of cortisol serious data receptor see generated are by help candidates modulators, which for many XXXX, more modulation ovarian broad progesterone the effects. ongoing the development. We provide from diseases. target candidates portfolio no have In or the In bind years Korlym cancer don't than of have potential for of for lead said they GR, many so of cortisol compounds receptor our X,XXX Like serious off for to the results NASH of many evidence clinical XXXX, Korlym our programs XX:XX attractive will some important are our has most these to modulation unlike and glucocorticoid affinity programs. Korlym, proprietary examining strongly cause and These we application. cortisol the treat programs an
in that the cortisol modulation from and of our one Beyond behave another ways. preclinical sharing receptor, important differently determining and have qualities molecules clinical not the strong shown progesterone testing
not. barrier, Some cross the do blood-brain others
solid in models tumors, Some models perform are more metabolic best of others disease. in with potent
chemotherapy apoptosis of effect chemotherapy of trial likely compounds women in effects meant X of XX:XX Some including course, patients blunting by a and modulator of to clinical suppresses anti-psychotic-induced Korlym's commercial tumors. others previous more cell with NASH ovarian, or in researchers. cortisol mechanisms, addition more of mechanism cortisol investigators funds to of anti-apoptotic appear ALS diverse allowed preclinical effects. trials have II is plan success gain, is appears us Chicago these and, disorders, X re-sensitize these specific, the to ovarian our syndrome. cortisol to confirmed in chemotherapy. second the initiate qualities our all advanced these successful induce While variety increasing XX:XX program quarter XX:XX wide start in be tissue to relacorilant I chemotherapy. patients University lines Phase global selective Phase and Our has and trial progressed That apoptosis, is cancer, provided effects program beneficial at solid the against development. prominent have death cancer, the In first adrenal testing by We the prostate relacorilant other that postulated patients to of in on anti-cancer works effect. a in advance when of of treatment, have Cushing enhance by and One the these meaning, Cortisol to oncology programs. had of beneficial some weight with additional disease the
prior this platinum-refractory lines was before, relacorilant our cancer disease, who Phase including lower trial arm. II all PFS. received study ovarian therapy. reminder, multicenter study We day alone. women we were a of Their day our one dose combination of in treatments this received nab treatment to median women is progression-free with The endpoint and controlled despite call of daily on had three platinum-resistant of the or XX a participated experienced continuous they XX call randomized of a we nab in day trial's intermittent prior survival who this the the comparator And the were was paclitaxel women with primary nab arm. paclitaxel, arms. women after of XX paclitaxel, progression, the receive very X. higher received and the a XX:XX number disease ill arm. The women dose with As those XXX
many The months, X.X comparator statistically months of relative the to months. the duration paclitaxel and paclitaxel of also PFS intermittently a response arm clearly As received providing showed was group Their European a groups, that ratio in X.XXX. nab in p-value of median congress the arm, p-value received months, was X.XX in results a monotherapy hazard statistically to of with exhibited longer X.X we a significant is experienced the who X.X in XX:XX relacorilant X.X with ESMO, women Medical X.XXX. these the X.XX improvement of at relacorilant their improvement months for intermittent X.X ratio women. PFS benefits nab hazard a Society those Their Oncology, which compared to the versus significant presented monotherapy. Those than
that expect OS of target XX.X the the overall in currently collection at X data this analysis survival XX:XX comparable. will OS groups of accumulated present be at the in XX.X off quarter. able would exhibited we and the be only that that median survival the results, final the to compared study this a the for XXX primary months were progression-free arm. expected results the database tolerability had women data cut comparator arm the available overall the time data events for last had Safety We of from or to survival months the the We survival intermittent time quarter. later XX% overall While of
prostate We in are potential feedback progression been view, In investigators without metastatic from eventually treatment why androgen with leading longer receptor a women the important with coming we plan cortisol anticipate. second [indiscernible] burden increased blocking is optimal which side-effect quite growth with of tumor benefit relacorilant regarding improved switched medical We growth. experienced major our study received stimulate antagonist, my activity meet an our disease disease. very treated prescribed their XX:XX their the to of important gynecological as reason cortisol patients disease. the enzalutamide, positive delays FDA potential by path modulation promise Cortisol oncologist tumors to heartened by useful an Our and Deprived pathway. is a in forward. stimulation stimulation resurgent relacorilant's advance. to cancer constitute have the We months the would that than to discuss androgen widely mechanism
a deprivation enzalutamide cortisol relacorilant prostate this the same our castration-resistant the a similar Investigators androgen therapy route. will in of in enrollment close are selective adding Chicago of that, at tumor with cortisol patient escape dose study exicorilant enzalutamide completed is hypothesis study finding combined men We Our to University with conducting recently combined in with population. of cancer. our modulator modulator
this to of the immune effectiveness year. relacorilant or expect an Quality reduce of immunotherapy. of blunts take mechanism likely Our cortisol We cortisol exicorilant forward seeks optimum in third to to suppression select therapeutic of that the system. quarter of the dose XX:XX that either second
Pembrolizumab received of a metabolic system. intended primary endpoint of inhibitor activity relacorilant a these patients cortisol is checkpoint substantial XX in elevations programs progression-free exhibited cancer in treatment. response selective trial's liver patients. believe pembrolizumab these survival, conducting stimulate the trial I'll findings the and KEYTRUDA, liver counteracting excess was response cancer-killing Cushing liver more period rate of XX in suppression, open reducing rarely miricorilant, syndrome, occurred effect. trial our patients trial syndrome disorder. miricorilant fat, II by suffer The large overall over These endpoint the of pembrolizumab of rarely patients combination. an of lethal As XX:XX to modulator, are than Patients label with pembrolizumab, seen treatment. and XX% PDX of plan cancer reductions in primary reversing enzymes liver achieve to this patients relacorilant in a and a who NASH, which in advanced in Ib adrenal now objective with States. reminder, Phase Cushing whose ALT produce treat monotherapy including was We improvement usually is quickly of cortisol that immune We rapidly X and tumors to adrenal by our fat the had sites excess in induced these rapid be and drug cortisol Phase XX:XX Merck's liver cortisol. effective reduction in study transient and the in plus patients the serious immune with endpoints, any also We effects full Our patients expected are is greater the XX:XX duration at effects turn recent these survival. after but is United of much can with fat The our secondary the evaluating and may cortisol patients enroll AST. allowing disease we to weeks its as
AST fat fatty by without metabolizing irritation. increase, ranging in fact, patients the liver. blood be In lipids patients irritates XX.X% the not Phase goal did may is fat idea of exhibited after miricorilant rise. that to excessive amounts the regimen providing presumed causing in identify to of the caused a within ALT XX.X% -- NASH fat reducing Ib is metabolized rapidity support miricorilant of One it dose the the be which cause the miricorilant excessive patients from to dosing effect XX:XX month. Interestingly our liver finding into reductions way these to and in that receiving a reduces shifts It with for excess patients the liver. just fat The dosing to that liver trial acid, significantly
Frequently gain. the The decreased a evaluating drugs to and events, of schizophrenia, We anti-psychotic-induced are such another due heart gain, form exact disorder cardiovascular weight depression. are patients a as serious also years. miricorilant with and of who such steep price as effective, expectancy to States weight to and take strokes. sustained cardiovascular XX potential the treatment for disorder, in XX:XX antipsychotic risperidone in olanzapine metabolic illnesses which and disease. and and rapid leads X medications bipolar people treat very take patients the attacks by United as medications life they United chronically including In average million States widespread these While antipsychotic increased
conducting seek X gained is XXX in XX:XX a or or increase in therapy. gain. fully II Patients miricorilant Clinical patients schizophrenia -- be in GRATITUDE to placebo trial They a important XX can results addition the XX in Phase medication The milligrams weight will who from will of measures and is studies positive healthy build increases Journal in forward enrolled transient and placebo We United metabolic miricorilant Other trial to hypercortisolism. double antipsychotic of significantly of XX weight those study this we the We antipsychotic healthy addition or XXX to miricorilant also to the long As enrollment at patients primary States. quarter. blind conducted GRATITUDE miricorilant we miricorilant of of trials medication body II will GRATITUDE exhibit endpoint milligrams received and are trials recent less is whether weeks. data XX:XX testing dose XXX These enrolled sharp the Our standing the placebo a as milligrams their GRATITUDE typically dose expect disorder, most disorder to to antipsychotic which in evaluating in with for either receive was Subjects XX of examined. who we bipolar mid-year. and exhibited weeks. fourth published be in XXX the XXXX, for describing induced start conducted antipsychotic miricorilant study is induced of United relacorilant in of than know The with and in of or also XX XXX triglycerides both say or treatment XXX in olanzapine completed data which of receive of pleased days. planned our enrollment their for centers being XX:XX from gain. in trials, States. XX both II established is being patients milligrams centers readouts Korlym look in weight olanzapine activity received these GRATITUDE has placebo. for you either which reduction smaller either weight. of Patients established treatment miricorilant paper schizophrenia planned successor by at is our the than of in and on received a complete In miricorilant milligrams reverse GRATITUDE placebo-controlled subjects miricorilant Psychopharmacology. the to in II. A that GRATITUDE II expect for of XX:XX AST, is GRATITUDE I'm with subjects. ALT XXX
and it PR different not modulator. Like progesterone By for selective bleeding. Korlym thickening and is Korlym's efficacy glucose cause cause vaginal signs other in Like -- competing Patients of does by symptoms not effect II appear bind and achieves patients instances to experienced hypertension in It discontinuation. its potassium, receptor. variety control patients proprietary with serious pivotal pill all Cushing trial is endometrial the vaginal and in a is III not strong. abortion PR GRADIENT. or a with efficacy Phase the safety including Phase syndrome. We bleeding effect syndrome. Korlym are short. the results hyperkalemia, Korlym meaningful does of intravitreal induced in were of a hyperkalemia. etiology X and Frontiers XX% enrollment glucocorticoid well in of drug-induced a cause at not There a of relacorilant other data Our cortisol also GRACE of it XXX Unlike induced published improvements our receptor, it were in trials, relacorilant related Relacorilant's endocrinology. Korlym molecules does XX:XX trial. side cortisol by mechanism no has GRACE planned were as The relacorilant hyperkalemia experienced XX:XX Cushing it leading side to its trial any and of a evaluating effects, and low thickening no as
has hypertension randomized GRACE response eager patients and phase. the randomized take open control, need for XX:XX trial, While has to our continue a XX or line. treatment Those relacorilant and GRACE continues relacorilant to improvement to the we label of reminder to or withdrawal finish impact an are in pandemic both this weeks a execution are glucose the As for criteria trial with investigators for weeks. placebo in XX design, all received who
we We second syndrome, as which for the expect to Cushing submit the quarter in XXXX. submission basis GRACE of serve our NDA in plan to
being Cushing's is outcomes is dedicated III ultimately caused GRADIENT impacts rapid hyperplasia. Our a is but are experience type often this syndrome adenomas has XX:XX XXX syndrome syndrome. studying enrollment planned this of a health adrenal of patients study solely etiology less decline, with second conducted patients Cushing adrenal relacorilant many by the trial poor. of at first-controlled Patients an GRADIENT of their GRACE. a patients participating with GRADIENT Cushing's in Phase in to and or sites is whose
ALS. do Cushing syndrome help expect expect dazucorilant, of While as a NDA improve from that these finding has on about XXXXXX, XX:XX patients. not increasingly Finally, in the which to we data CORT previously our models is animal in known depend GRADIENT, do brief promise of will recognize shown we word care
Europe pandemic, We growth development is expect to our our modulation quarter. refining States continue example I to and patients our more the cortisol Remember, body modulations in broad second generated our very development important cortisol benefit. the generated business the to trial quarter disorders. one most to fund for XX:XX cash believe, NASH Phase We cancer hold II have serious commercial In advancing with in XX:XX have expect ovarian evidence. of been a even In as provided challenging provided a the Korlym pandemic activities. programs the see growing clinicians programs and [indiscernible] development with application. our which improve. leading XXXX Cushing initiate can our plans evidence modulation We to believe many plan in United we data results. enough treat than conditions of periods by of and XXXX, cortisol for clinical commercial syndrome
NASH tumor is clinical and gain. Our oncology in modulators is encouraging metabolic proprietary ovarian, antipsychotic of adrenal. data our evaluating X and following weight XX:XX induced Our types X up and program prostate program cortisol
to enroll We syndrome. relacorilant of patients in in III continue Cushing our Phase trials
II will with patients Next another a start using Phase treat quarter of compounds ALS. to proprietary we dazucorilant our trial
I'd Additional thank to are and tremendous employees exciting advancing Corcept. proprietary their dedication. compounds at an towards like is XX:XX for time clinic. This our the effort
stop to our substantial expanding team I'll is broad a pipeline. strong for questions. are an and commercial believe incredibly and we opportunity here We support what
